Femasys Inc. (FEMY) AI Stock Analysis

Femasys Inc. is a biomedical company specializing in the women's healthcare market within the United States. Established in 2004 and headquartered in Suwanee, Georgia, the company develops non-surgical solutions for permanent birth control, including FemBloc and FemChec, alongside FemaSeed for artificial insemination. It also provides the FemCerv biopsy device for endocervical curettage and is advancing FemEMB for endometrial sampling to detect uterine cancer. In addition, Femasys commercializes the FemVue saline-air device internationally across the United States, Europe, Canada, Japan, and other markets, catering to obstetrics-gynecological physicians and reproductive endocrinologists.

Annual revenue grew from $1.2M in FY2021 to $2.3M in FY2025, representing a 5-year revenue CAGR of 17.2%. Revenue rose 52.0% in FY2024 and 40.8% in FY2025, though gross margin contracted to 62.0% in FY2025 from 66.6% in FY2024. Despite revenue growth, the company generated net losses of -$18.8M in FY2024 and -$18.6M in FY2025, with an operating margin of -767.0%. For the latest quarter ending June 30, 2026, quarterly revenue fell 18.9% year-over-year. TTM revenue stood at $2.3M, accompanied by an operating margin of -1526.7% and diluted EPS of -$3.28.

As of June 30, 2026, Femasys held $1.4M in cash and short-term investments against $4.8M in total debt, resulting in net debt of $3.3M. Total assets stood at $12.3M and shareholders' equity was $4.0M, supporting a current ratio of 2.14 and a debt-to-equity ratio of 1.19. In FY2025, operating cash flow was -$18.7M and capital expenditures were $525,007, producing negative free cash flow of -$19.2M. Over five years, the company's share count increased by 468.9%.

Femasys carries a market capitalization of $13.8M and an enterprise value of $24.6M. The stock trades at a price-to-sales ratio of 6.0x, above the 4.1x median of its US-listed Healthcare peers, while its enterprise value-to-revenue ratio is 10.7x. Over the past year, the shares dropped 88.9%, significantly lagging the 16.8% return for the S&P 500. Over a five-year period, the stock fell 98.8% compared to an 83.0% gain for the S&P 500 benchmark. At its last close of $1.65, FEMY traded near its 52-week low of $1.46.

Wall Street coverage consists of 1 Strong Buy and 2 Buy ratings, with no Hold or Sell recommendations. The mean price target is $14.33, representing a 768.7% premium over the last closing price of $1.65. For the fiscal year ending December 31, 2026, analysts forecast revenue of $2.1M and an EPS of -$2.60. For the following fiscal year, 2 analysts project revenue to reach $8.9M, a 328.4% increase. Femasys has beaten EPS estimates in each of the last 4 quarters, with next earnings scheduled for November 13, 2026.

This page is an AI-written research summary of Femasys Inc. (FEMY). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: FEMY income statement, FEMY balance sheet, FEMY key metrics, FEMY analyst forecast, FEMY chart. See the FEMY stock overview for the latest quote and news.